For research use only. Not for therapeutic Use.
Larotaxel is a semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
| Catalog Number | R046723 |
| CAS Number | 156294-36-9 |
| Synonyms | (αR,βS)-β-[[(1,1-Dimethylethoxy)carbonyl]amino]-α-hydroxybenzenepropanoic Acid (1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-Bis(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cycl |
| Molecular Formula | C₄₅H₅₃NO₁₄ |
| Purity | ≥95% |
| Target | Apoptosis |
| Storage | -20°C |
| Reference | </br>1:Characterization of metabolites of larotaxel in rat by liquid chromatography coupled with Q exactive high-resolution benchtop quadrupole orbitrap mass spectrometer. Liu Z, Hou P, Liu L, Qian F.Xenobiotica. 2017 Mar 10:1-10. doi: 10.1080/00498254.2017.1297872. [Epub ahead of print] PMID: 28281396 </br>2:Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel solution with larotaxel-loaded folate receptor-targeting amphiphilic copolymer-modified liposomes. Lu XF, Zhou Y, Zhang J, Wang GQ.Xenobiotica. 2017 May;47(5):416-422. doi: 10.1080/00498254.2016.1195936. Epub 2016 Jun 20. PMID: 27324077 </br>3:Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel. Li J, Li A, Li M, Qiao Y, Zhang H.Anticancer Agents Med Chem. 2016;16(7):875-80. PMID: 26830032 </br>4:Determination of larotaxel and its metabolites in rat plasma by liquid chromatography-tandem mass spectrometry: application for a pharmacokinetic study. Liu Z, Zhang L, Ju P, Hou P, Zhang Y, Tang X, Bi K, Chen X.J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Feb 1;947-948:132-8. doi: 10.1016/j.jchromb.2013.12.029. Epub 2013 Dec 31. PMID: 24413022 </br>5:Parenteral formulation of larotaxel lipid microsphere tackling poor solubility and chemical instability. Teng F, Yang H, Li G, Lin X, Zhang Y, Tang X.Int J Pharm. 2014 Jan 2;460(1-2):212-9. doi: 10.1016/j.ijpharm.2013.10.039. Epub 2013 Oct 29. PMID: 24184034 </br>6:Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, Bellmunt J, Peters F, Le-Guennec S, Cerbone L, Risse ML, Machiels JP.Oncology. 2013;85(4):208-15. doi: 10.1159/000354085. Epub 2013 Sep 24. PMID: 24080920 </br>7:Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution. Liu Z, Feng Y, Zhang L, Li G, Geng L, Cui Y, Teng F, Tang X, Bi K, Chen X.Cancer Chemother Pharmacol. 2013 May;71(5):1131-9. doi: 10.1007/s00280-013-2104-2. Epub 2013 Feb 15. PMID: 23412629 </br>8:Cloud-point extraction combined with HPLC for determination of larotaxel in rat plasma: a pharmacokinetic study of liposome formulation. Ma H, You J, Liu Y.J Sep Sci. 2012 Jun;35(12):1539-46. doi: 10.1002/jssc.201200039. Epub 2012 Jun 18. PMID: 22707410 </br>9:Development of a UPLC-ESI-MS/MS method for the determination of larotaxel in beagle dog plasma: application to the pharmacokinetic study. Liu Z, Zhang B, Liu Z, Li S, Li G, Geng L, Zhao X, Bi K, Tang X, Chen X.Anal Bioanal Chem. 2012 Apr;403(1):323-30. doi: 10.1007/s00216-012-5763-7. PMID: 22302171 </br>10:Isolation and characterization of process-related impurities and degradation products in larotaxel. Che X, Shen L, Xu H, Liu K.J Pharm Biomed Anal. 2011 Jul 15;55(5):1190-6. doi: 10.1016/j.jpba.2011.03.036. Epub 2011 Apr 6. PMID: 21530132 |
